| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1334 | 2019 |
| NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 381 | 2021 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 271 | 2020 |
| EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma J Rosenberg, SS Sridhar, J Zhang, D Smith, D Ruether, TW Flaig, ... Journal of Clinical Oncology 38 (10), 1041-1049, 2020 | 240 | 2020 |
| NCCN guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 227 | 2022 |
| Augmenting antitumor immune responses with epigenetic modifying agents E Héninger, TEG Krueger, JM Lang Frontiers in immunology 6, 29, 2015 | 224 | 2015 |
| Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 21 (10), 1067-1096, 2023 | 192 | 2023 |
| The calcineurin-NFAT pathway and muscle fiber-type gene expression SJ Swoap, RB Hunter, EJ Stevenson, HM Felton, NV Kansagra, JM Lang, ... American Journal of Physiology-Cell Physiology 279 (4), C915-C924, 2000 | 173 | 2000 |
| Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma JM Lang, MR Kaikobad, M Wallace, MJ Staab, DL Horvath, G Wilding, ... Cancer Immunology, Immunotherapy 60, 1447-1460, 2011 | 156 | 2011 |
| Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance M Kohli, Y Ho, DW Hillman, JL Van Etten, C Henzler, R Yang, JM Sperger, ... Clinical Cancer Research 23 (16), 4704-4715, 2017 | 143 | 2017 |
| A role for microfluidic systems in precision medicine JM Ayuso, M Virumbrales-Muñoz, JM Lang, DJ Beebe Nature communications 13 (1), 3086, 2022 | 135 | 2022 |
| Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting J Luo, G Attard, SP Balk, C Bevan, K Burnstein, L Cato, A Cherkasov, ... European urology 73 (5), 715-723, 2018 | 132 | 2018 |
| Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer DG McNeel, HA Smith, JC Eickhoff, JM Lang, MJ Staab, G Wilding, G Liu Cancer Immunology, Immunotherapy 61, 1137-1147, 2012 | 105 | 2012 |
| Current controversies in the management of biochemical failure in prostate cancer JY Bruce, JM Lang, DG McNeel, G Liu Clin Adv Hematol Oncol 10 (11), 716-722, 2012 | 81 | 2012 |
| The VerIFAST: an integrated method for cell isolation and extracellular/intracellular staining BP Casavant, DJ Guckenberger, SM Berry, JT Tokar, JM Lang, DJ Beebe Lab on a Chip 13 (3), 391-396, 2013 | 78 | 2013 |
| Expression and immunotherapeutic targeting of the SSX family of cancer–testis antigens in prostate cancer HA Smith, RJ Cronk, JM Lang, DG McNeel Cancer research 71 (21), 6785-6795, 2011 | 69 | 2011 |
| Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation JM Sperger, LN Strotman, A Welsh, BP Casavant, Z Chalmers, S Horn, ... Clinical Cancer Research 23 (3), 746-756, 2017 | 66 | 2017 |
| Circulating tumor cells: getting more from less JM Lang, BP Casavant, DJ Beebe Science translational medicine 4 (141), 141ps13-141ps13, 2012 | 65 | 2012 |
| A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells BP Casavant, R Mosher, JW Warrick, LJ Maccoux, SMF Berry, JT Becker, ... Methods 64 (2), 137-143, 2013 | 64 | 2013 |
| High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1 JL Schehr, ZD Schultz, JW Warrick, DJ Guckenberger, HM Pezzi, ... PLoS One 11 (7), e0159397, 2016 | 63 | 2016 |
